Findings

What do systematic reviews say?

44 questions · 46 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 6.5%GRADE not reported 10 · 21.7%Very low 16 · 34.8%Low 10 · 21.7%Moderate 7 · 15.2%High 0 · 0%

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Relapse · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes global state: Relapse (any reason) ‐ long term Number of… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 2.13 [0.84, 5.43]
1 study · 63 participants
Very low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Mental state ‐ improvement · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.24 [0.98, 1.57]
2 studies · 467 participants
Moderate

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported